THOMSON MEDICAL GROUP LIMITED (A50) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of THOMSON MEDICAL GROUP LIMITED S$0.05, price S$0.05, upside +0.0%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch THOMSON MEDICAL GROUP LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range 0.0400 SGD – 0.0898 SGD · fair‑value band 0.0302 SGD – 0.0614 SGD · the 0.0510 SGD price screens below the 0.0510 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow THOMSON MEDICAL GROUP in your weekly email
Every Wednesday you see whether THOMSON MEDICAL GROUP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinics and facilities.
Show more
Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinics and facilities. It also offers urgent care services, such as basic resuscitation, ECG, vaccinations, IM/IV fluid and IV antibiotic administration, surgeries and procedures, wound care and stitching, and X-ray and basic laboratory tests; health screening services; services related to skin and aesthetics, and pain and rehab management; and herbal tea. In addition, the company provides specialized services, such as women's health, children's health, fertility and family planning, eye health, general surgery, urology, preventive health and healthy ageing, diagnostic imaging, breast health, cardiology, respiratory medicine and critical care, endocrinology, dermatology, day surgery, surgical care, counselling and therapy, traditional Chinese medicine (TCM), as well as bone, joint, gynecological oncology, dentistry, and spine health. It offers its products and services under the Thomson Women's Clinic, Thomson Fertility Centre, Thomson Paediatric Clinic, Thomson Specialists, Thomson Chinese Medicine, Thomson Surgical Centre, Thomson Dental Centre, Thomson Hospital Kota Damansara, TMC Fertility, TMC Care Pharmacy, FV Hospital, and FV Saigon Clinic brands. Thomson Medical Group Limited was founded in 1979 and is based in Singapore.
Stock analysis
THOMSON MEDICAL GROUP LIMITED (A50) currently trades at 0.0510 SGD, while our model-based Fair Value estimate is 0.0510 SGD, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.0300 SGD per share, and 0 of the 7 models we run sit above the 0.0510 SGD price.
Bear case: the Multiples group reads lowest at 0.0100 SGD, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.0302 SGD (bear) to 0.0614 SGD (bull), the price of 0.0510 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
THOMSON MEDICAL GROUP LIMITED reported revenue of 420M SGD in FY2025 versus 334M SGD in FY2021, a compound +5.9%/yr. Reported net income was −29.7M SGD in FY2025.
Key figures
Market cap 1.3B SGD (≈ $1.1B) · P/S ratio 3.22 · Net margin −7.1% · Return on equity −5.2% · Return on assets (EBIT) 3.8% · Operating margin 11.1% · Revenue (TTM) 427M SGD · Revenue growth (YoY) −16.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 0%, A50 screens richer than that median.
Fair Value models
Bear 0.0302 SGDFair Value 0.0510 SGDBull 0.0614 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +9.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
20.3% (2020) → 6.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +22.4% a year for the price.
Compare THOMSON MEDICAL GROUP LIMITED with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on assets1.5% · Below median
Net margin (TTM)−7.0% · Bottom 25%
Operating margin (TTM)11.1% · Above median
Growth and dividend
Revenue growth−16.9% · Bottom 25%
Balance sheet
Debt / equity2.04× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "THOMSON MEDICAL GROUP LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/A50
Frequently asked questions
Is THOMSON MEDICAL GROUP LIMITED (A50) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 0.0510 SGD versus a price of 0.0510 SGD, about +0% upside (fairly valued).
What is the fair value of A50?
Our model-based fair value for THOMSON MEDICAL GROUP LIMITED is 0.0510 SGD (as of Oct 1, 2026), built from audited fundamentals. The current price: 0.0510 SGD.
What is the quality score of A50?
THOMSON MEDICAL GROUP LIMITED has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for THOMSON MEDICAL GROUP LIMITED (A50)?
Our model-based price target is the fair value of 0.0510 SGD (as of Oct 1, 2026) from 9 valuation models. Cautious scenario 0.0302 SGD, optimistic scenario 0.0614 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the THOMSON MEDICAL GROUP LIMITED stock forecast for 2026?
Our models put fair value at 0.0510 SGD, about +0% upside versus a price of 0.0510 SGD (fairly valued). Cautious scenario 0.0302 SGD, optimistic scenario 0.0614 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of THOMSON MEDICAL GROUP LIMITED (A50)?
THOMSON MEDICAL GROUP LIMITED reported trailing-twelve-month revenue of about 427M SGD (latest available figure, as of Oct 1, 2026).
What growth is priced into THOMSON MEDICAL GROUP LIMITED (A50)?
For today's price to be fair in a discounted-cash-flow model, THOMSON MEDICAL GROUP LIMITED would have to grow free cash flow by +24.9 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.8 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of A50 use?
Our models discount THOMSON MEDICAL GROUP LIMITED at 9.6 %: a base by market capitalisation (small), damped by beta 0.29, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For THOMSON MEDICAL GROUP LIMITED that is +24.9 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has THOMSON MEDICAL GROUP LIMITED (A50) delivered so far?
Over the past 5 years revenue at THOMSON MEDICAL GROUP LIMITED grew +11.8 % a year. The price currently implies +24.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of THOMSON MEDICAL GROUP LIMITED (A50) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into THOMSON MEDICAL GROUP LIMITED (+24.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of THOMSON MEDICAL GROUP LIMITED (A50)?
The free-cash-flow yield on the price is 3.78 %: that much free cash flow THOMSON MEDICAL GROUP LIMITED produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of THOMSON MEDICAL GROUP LIMITED (A50)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For THOMSON MEDICAL GROUP LIMITED it is 0.0510 SGD per share (as of Oct 1, 2026), against a price of 0.0510 SGD. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is THOMSON MEDICAL GROUP LIMITED stock overvalued or undervalued in 2026?
As of Oct 1, 2026, A50 trades below its calculated fair value: price 0.0510 SGD, fair value 0.0510 SGD, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of A50?
No. The price is what the market pays today (0.0510 SGD); the fair value is what the company's own numbers justify (0.0510 SGD). For THOMSON MEDICAL GROUP LIMITED the two are 0.0000 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is THOMSON MEDICAL GROUP LIMITED worth?
The market values THOMSON MEDICAL GROUP LIMITED at about 1.3B SGD (market capitalisation, as of Oct 1, 2026). Per share that is 0.0510 SGD; our models calculate a fair value of 0.0510 SGD per share.
What do the bullish and bearish scenarios say about A50?
Our models span a range for THOMSON MEDICAL GROUP LIMITED: cautious scenario 0.0302 SGD, base 0.0510 SGD, optimistic 0.0614 SGD per share (as of Oct 1, 2026, price 0.0510 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of THOMSON MEDICAL GROUP LIMITED (A50)?
Balance-sheet figures for THOMSON MEDICAL GROUP LIMITED (as of Oct 1, 2026): return on equity −5.2%, debt of 2.04 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is A50 from its 52-week high?
THOMSON MEDICAL GROUP LIMITED trades at 0.0510 SGD, about 20% below its 52-week high of 0.0640 SGD and at the low of 0.0510 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0510 SGD is for.
Which stocks are comparable to THOMSON MEDICAL GROUP LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is THOMSON MEDICAL GROUP LIMITED stock attractive at the current price?
The data as of Oct 1, 2026: price 0.0510 SGD, calculated fair value 0.0510 SGD (+0%), Quality Score 46/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of A50 calculated?
We run THOMSON MEDICAL GROUP LIMITED through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0510 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. THOMSON MEDICAL GROUP LIMITED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of THOMSON MEDICAL GROUP LIMITED (A50)?
The closing price on Oct 1, 2026 was 0.0510 SGD. Our model-based fair value is 0.0510 SGD, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with THOMSON MEDICAL GROUP LIMITED right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (0.0302 SGD to 0.0614 SGD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of THOMSON MEDICAL GROUP LIMITED
How large is the market capitalisation of THOMSON MEDICAL GROUP LIMITED (A50)?
The market capitalisation of THOMSON MEDICAL GROUP LIMITED is 1.3B SGD (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of THOMSON MEDICAL GROUP LIMITED (A50)?
The price-to-sales ratio of THOMSON MEDICAL GROUP LIMITED is 3.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of THOMSON MEDICAL GROUP LIMITED (A50)?
The net margin of THOMSON MEDICAL GROUP LIMITED is −7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of THOMSON MEDICAL GROUP LIMITED (A50)?
The return on equity (ROE) of THOMSON MEDICAL GROUP LIMITED is −5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of THOMSON MEDICAL GROUP LIMITED (A50)?
On an EBIT basis the return on assets of THOMSON MEDICAL GROUP LIMITED is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of THOMSON MEDICAL GROUP LIMITED (A50)?
The operating margin of THOMSON MEDICAL GROUP LIMITED is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at THOMSON MEDICAL GROUP LIMITED (A50)?
Revenue at THOMSON MEDICAL GROUP LIMITED is growing −16.9% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at THOMSON MEDICAL GROUP LIMITED (A50)?
Earnings per share at THOMSON MEDICAL GROUP LIMITED are growing −3.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does THOMSON MEDICAL GROUP LIMITED (A50) carry?
The net debt of THOMSON MEDICAL GROUP LIMITED is 991M SGD (fiscal year 2025, ≈ 19.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch THOMSON MEDICAL GROUP LIMITED in the live analysis
One click puts THOMSON MEDICAL GROUP LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
